Cardiome -- CRME Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cardiome -- CRME

CRME 2.330

-2.1%

May 16 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (13)	7/12/2006 8:28:02 PM
From: former_pgs	of 285

Some feedback: Ibutilide isn't getting much use here other than as an occasional adjunct to electrical conversion. Indirectly then, we can assume that ibutilide's SE profile, given the efficacy, isn't making anyone happy. If we toss out electrical conversion (mostly for unstable cases) and focus on the drugs currently used around here, to my knowledge ibutilide isn't high on the list. Check out amiodarone and propafenone as they appear to be getting good use here depending on extent of underlying disease. I'm told that conversion rates are > 55-60% when skillfully used (whatever that means). They are willing to tolerate the SEs of these drugs so perhaps that type of comparison (amiodarone / propafenone vs. rsd1235) may help you handicap the doc's actions vis-a-vis the safety / efficacy trade-off when rsd1235 hits the market as a competitor. cheers.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next